Last reviewed · How we verify
NCT02955316: IRONS
Irritable Bowel Syndrome Survey in Gastroenterological Adult Outpatients in China
trial in Irritable Bowel Syndrome (IBS) in 3,000 participants. Completed in 30 September 2017.
30 September 2017
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 3,000 |
| Start date | 10 February 2017 |
| Primary completion | 30 September 2017 |
| Estimated completion | 30 September 2017 |
| Sites | 1 location across China |
Conditions studied
- Irritable Bowel Syndrome (IBS) — all drugs for Irritable Bowel Syndrome (IBS) →
Sponsor
AstraZeneca — full company profile →
Who can join
Eligibility, any sex, with Irritable Bowel Syndrome (IBS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to estimate the overall prevalence of IBS medically diagnosed and diagnosed using Rome III or IV criteria in GI adult outpatients in China.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02955316
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Irritable Bowel Syndrome (IBS)
Currently open trials in the same condition.
- NCT07481422 — Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsules in Treatment of Irritable Bowel Syndro · Phase 1, PHASE2 · recruiting
- NCT07261826 — Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics · recruiting
- NCT07000227 — Mechanism of FODMAP Restriction on FGID Patients · NA · recruiting
- NCT06647043 — Evaluate the Effect of Synbiotics in Irritable Bowel Syndrome · NA · recruiting
- NCT06668922 — Irritable Bowel Syndrome and Control Volunteers: Diet Challenge · NA · recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02955316 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 7 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02955316.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing